Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutic Com
(NQ:
SAGE
)
10.99
+0.52 (+4.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sage Therapeutic Com
< Previous
1
2
3
4
Next >
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
August 04, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 04, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at Upcoming May Investor Conferences
May 03, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
May 02, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
April 18, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Stifel 2023 CNS Days
March 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Appoints Jessica Federer to Board of Directors
March 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
March 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
February 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
February 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Biogen Inc.
Via
GlobeNewswire
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
February 02, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
January 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
January 03, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
December 06, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 23, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
November 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
November 14, 2022
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Retirement
Exposures
Pension
Product Safety
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
November 08, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
November 01, 2022
From
Sage Therapeutics
Via
Business Wire
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 25, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
October 17, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Mental Health Claims up 75% Since 2019
September 23, 2022
Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their mental health benefits. According to the Canadian...
Via
PressReach
Mental Health Claims up 75% Since 2019
September 23, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 23, 2022 – Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75%...
Via
FinancialNewsMedia
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
September 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.